



April 26, 2017

## **Insmmed to Host First Quarter 2017 Financial Results Conference Call on Wednesday, May 3, 2017**

BRIDGEWATER, N.J., April 26, 2017 (GLOBE NEWSWIRE) -- Insmmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its first quarter 2017 financial results on Wednesday, May 3, 2017.

Will Lewis, president and chief executive officer, will host a conference call for investors beginning at 8:30 a.m. ET on Wednesday, May 3, 2017 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (844) 707-0669 (domestic) or (703) 639-1223 (international) and referencing conference ID number 3999935. The call will also be webcast live on the internet on the company's website at [www.insmed.com](http://www.insmed.com).

A replay of the conference call will be accessible approximately two hours after its completion through May 17, 2017 by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) and referencing conference ID number 3999935. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at [www.insmed.com](http://www.insmed.com).

### **About Insmmed**

Insmmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE® (liposomal amikacin for inhalation) for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung infections caused by MAC in the United States or European Union (EU). Insmmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-CF bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare disorders, including pulmonary arterial hypertension (PAH). For more information, visit [www.insmed.com](http://www.insmed.com).

"Insmmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.

Investor Contact:

Laura Perry or Heather Savelle

Argot Partners

212-600-1902

[laura@argotpartners.com](mailto:laura@argotpartners.com)

[heather@argotpartners.com](mailto:heather@argotpartners.com)

 Primary Logo

Source: Insmmed Incorporated

News Provided by Acquire Media